PMID- 28718426
OWN - NLM
STAT- MEDLINE
DCOM- 20180604
LR  - 20240109
IS  - 2405-8025 (Electronic)
IS  - 2405-8025 (Linking)
VI  - 3
IP  - 1
DP  - 2017 Jan
TI  - Targeting TGF-beta Signaling in Cancer.
PG  - 56-71
LID - S2405-8033(16)30186-8 [pii]
LID - 10.1016/j.trecan.2016.11.008 [doi]
AB  - The transforming growth factor (TGF)-beta signaling pathway is deregulated in many 
      diseases, including cancer. In healthy cells and early-stage cancer cells, this 
      pathway has tumor-suppressor functions, including cell-cycle arrest and 
      apoptosis. However, its activation in late-stage cancer can promote 
      tumorigenesis, including metastasis and chemoresistance. The dual function and 
      pleiotropic nature of TGF-beta signaling make it a challenging target and imply the 
      need for careful therapeutic dosing of TGF-beta drugs and patient selection. We 
      review here the rationale for targeting TGF-beta signaling in cancer and summarize 
      the clinical status of pharmacological inhibitors. We discuss the direct effects 
      of TGF-beta signaling blockade on tumor and stromal cells, as well as biomarkers 
      that can predict the efficacy of TGF-beta inhibitors in cancer patients.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Colak, Selcuk
AU  - Colak S
AD  - Department of Molecular Cell Biology, Cancer Genomics Centre Netherlands, Leiden 
      University Medical Center, Postbus 9600, 2300 RC Leiden, The Netherlands. 
      Electronic address: S.Colak@lumc.nl.
FAU - Ten Dijke, Peter
AU  - Ten Dijke P
AD  - Department of Molecular Cell Biology, Cancer Genomics Centre Netherlands, Leiden 
      University Medical Center, Postbus 9600, 2300 RC Leiden, The Netherlands; Ludwig 
      Institute for Cancer Research, Science for Life Laboratory, Uppsala University, 
      Uppsala, Sweden; Department of Cancer Signaling, Faculty of Medicine, University 
      of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan. Electronic address: 
      P.ten_Dijke@lumc.nl.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20170103
PL  - United States
TA  - Trends Cancer
JT  - Trends in cancer
JID - 101665956
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Smad Proteins)
RN  - 0 (Transforming Growth Factor beta)
SB  - IM
MH  - Animals
MH  - Biomarkers, Tumor/metabolism
MH  - Drug Resistance, Neoplasm
MH  - Humans
MH  - Neoplasms/*drug therapy/metabolism
MH  - Precision Medicine
MH  - Signal Transduction
MH  - Smad Proteins/metabolism
MH  - Transforming Growth Factor beta/*antagonists & inhibitors
OTO - NOTNLM
OT  - TGF-beta
OT  - cancer
OT  - microenvironment
OT  - therapy resistance
OT  - tumor-initiating cells
EDAT- 2017/07/19 06:00
MHDA- 2018/06/05 06:00
CRDT- 2017/07/19 06:00
PHST- 2016/09/08 00:00 [received]
PHST- 2016/11/18 00:00 [revised]
PHST- 2016/11/28 00:00 [accepted]
PHST- 2017/07/19 06:00 [entrez]
PHST- 2017/07/19 06:00 [pubmed]
PHST- 2018/06/05 06:00 [medline]
AID - S2405-8033(16)30186-8 [pii]
AID - 10.1016/j.trecan.2016.11.008 [doi]
PST - ppublish
SO  - Trends Cancer. 2017 Jan;3(1):56-71. doi: 10.1016/j.trecan.2016.11.008. Epub 2017 
      Jan 3.